IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 14.450-14.900 for the period, compared to the consensus EPS estimate of 14.520. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IDXX. Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Down 1.3%

NASDAQ IDXX traded down $7.36 during trading on Thursday, hitting $571.87. The company’s stock had a trading volume of 431,856 shares, compared to its average volume of 527,508. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.90. The company has a market cap of $45.42 billion, a PE ratio of 42.11, a P/E/G ratio of 3.41 and a beta of 1.58. The business’s 50 day simple moving average is $587.21 and its 200-day simple moving average is $650.39. IDEXX Laboratories has a fifty-two week low of $485.40 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts anticipate that IDEXX Laboratories will post 14.58 EPS for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 in the last ninety days. 0.79% of the stock is owned by company insiders.

Institutional Trading of IDEXX Laboratories

Hedge funds have recently modified their holdings of the stock. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the third quarter valued at approximately $26,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $36,000. Johnson Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 1,475.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock valued at $40,000 after purchasing an additional 59 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in IDEXX Laboratories during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.